Skip to main content
SpringerLink
Log in

Durvalumab not cost effective for first-line treatment of advanced SCLC

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. Durvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer

Reference

  • Tong YH, et al. Cost-effectiveness analysis of durvalumab plus etoposide: platinum in the first-line therapy of extensive stage small-cell lung cancer from the Chinese payers' perspective. Tumori : 29 Jan 2021. Available from: URL: http://doi.org/10.1177/0300891620985309

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Durvalumab not cost effective for first-line treatment of advanced SCLC. PharmacoEcon Outcomes News 872, 13 (2021). https://doi.org/10.1007/s40274-021-7486-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-021-7486-5

Search

Navigation